403 related articles for article (PubMed ID: 28822777)
1. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.
Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ
Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
Cherney DZ; Perkins BA
Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
5. [New oral hypoglycemic drugs in diabetic kidney disease].
Dylewska M; Graczyk M
Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
[TBL] [Abstract][Full Text] [Related]
6. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
7. New progress in drugs treatment of diabetic kidney disease.
Wang J; Xiang H; Lu Y; Wu T; Ji G
Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
9. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
Bell DSH; Jerkins T
Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
[TBL] [Abstract][Full Text] [Related]
10. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
11. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Avogaro A; Delgado E; Lingvay I
Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
13. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
14. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
17. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of antidiabetic drugs.
Sørensen AM; Christensen MB
Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
[TBL] [Abstract][Full Text] [Related]
20. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
Lau DC; Teoh H
Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
